Impact of body mass index on the clinical outcomes of immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma: insights from gene expression and tumor-infiltrating immune cell profile
This study demonstrates that while body mass index (BMI) does not significantly influence outcomes for advanced clear-cell renal cell carcinoma patients treated with dual immune checkpoint inhibitor therapy, underweight patients experience significantly poorer survival when receiving ICI-VEGFR tyrosine kinase inhibitor combinations, a disparity potentially driven by the downregulation of angiogenesis-related pathways in underweight individuals.